BofA moves to No Rating on Patterson Companies (PDCO) after the company announced that it has signed a definitive agreement to be acquired by Patient Square Capital for $31.35 per share in cash. Despite current weakness in dental and companion animal health trends, the firm views the takeout valuation as “reasonable,” the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PDCO:
- Patterson Companies price target raised to $31 from $25 at Baird
- M&A News: Patterson Companies Stock (PDCO) Rallies on Patient Square Deal
- Albertsons terminates Kroger deal, Macy’s reports Q3 beat: Morning Buzz
- Patterson Companies downgraded to Market Perform from Outperform at Leerink
- Patterson Companies to be acquired by Patient Square for $31.35 per share